Alligator Bioscience AB (publ) (“Alligator” or the “Company”) has completed the share issue with pre-emption rights for the Company’s shareholders, which was resolved upon by the Board of Directors on December 15, 2020 pursuant to the authorization from the annual general meeting on May 5, 2020 (the “Rights Issue”). 
The subscription period ran from and including January 11, 2021 to and including January 25, 2021. Through the Rights Issue, Alligator receives approximately SEK 86 million before deduction of issue costs. 13 895 925 shares, corresponding to
approximately 97 per cent of the Rights Issue, were subscribed for by exercise of subscription rights (including subscription undertakings). Furthermore, 9 305 467 shares were subscribed for without subscription rights, corresponding to approximately 65 per cent of the Rights Issue. In total, the Rights Issue was
subscribed for at 163 per cent. Guarantee commitments made in connection with the Rights Issue will thus not be utilized. 

Press inquiries should be adressed to: